Early diagnosis is a powerful way to improve cancer survival. Investigative techniques need to be performed well to maximise performance and tolerability.
Early diagnosis and prevention of disease are two areas in which research is being undertaken because it has been established that one of the best ways to improve cancer survival rates is early diagnosis of the disease.
Unfortunately, at this time, medicine is poor at assessing individual risks. New genetic technologies and knowledge will allow personalised risk stratification for these patients. St Mark’s medical staff have already implemented genetic medicine into the clinical setting, and new technologies will vastly widen the scope of this.
The research undertaken at St Mark’s is already identifying and managing individuals at high risk of colorectal cancer. This process will soon expand to include those who are identified as having a moderate risk. Furthermore, employing genetic medicine to stratify an individual’s risk will allow for personalised surveillance regimes and a more tailored treatment plan.
St Mark’s is uniquely placed in this field because
- It is a world leader in understanding inherited colorectal cancer, hosting the world’s oldest and largest Poplyposis Registry
- It is home to a regional family cancer clinic
- St Mark’s is integrating genetic information in to its clinical practice
- The Wolfson Unit for Endoscopy is recognised as a world centre of excellence
- St Mark’s has the longest running IBD surveillance programme, designed to detect cancer at the earliest stage
- An established track record in the translation of new advances into clinical practice